Table 2.
HIV/HCV co-infected patients - summary of viral kinetics, pharmacokinetics and pharmacodynamics parameters per patient.
| Patient No | Response | Initial Viral Load (log IU/ml) |
First phase viral decline (log IU/ml) |
Viral decline at day 7 (log IU/ml) |
Viral decline at day 28 (log IU/ml) |
2nd phase viral decline slope (log/wk) |
Infected cell loss rate (Delta) |
IFN Cmax (log pg/ml) |
IFN half-life (days) |
Ec50 (log pg/ml) |
Nhill co- efficient |
IFN Cmax / EC90 |
Days above EC90 during 1st week (days) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| African-Americans | |||||||||||||
| 4 | NR | 6.80 | 0.55 | 0.05 | 0.10 | 0.00 | 0.01 | 3.99 | 1.63 | 3.78a | ND b | 0.65a | 0.00 |
| 20 | NR | 6.44 | 1.11 | 0.26 | 0.63 | 0.05 | 0.10 | 4.12 | 1.26 | 3.66 | 2.24 | 1.08 | 0.67 |
| 11 | NR | 6.81 | 0.58 | 0.10 | 1.04 | 0.13 | 0.18 | 3.97 | 1.93 | 3.65 | 1.64 | 0.54 | 0.00 |
| 14 | NR | 6.62 | 0.11 | 0.00 | 0.00 | 0.00 | 0.00 | 3.76 | 1.84 | 3.70a | ND b | 0.54a | 0.00 |
| 3 | NR | 6.20 | 0.26 | 0.19 | 0.40 | 0.04 | 0.04 | 3.66 | 2.62 | 3.70a | ND b | 0.31a | 0.00 |
| 7 | VB | 5.80 | 0.42 | 0.37 | 2.88 | 0.81 | 0.66 | 4.08 | 1.34 | 4.05 | 1.68 | 0.29 | 0.00 |
| 15 | VB | 6.00 | 0.72 | 0.00 | 0.92 | 0.47 | 0.19 | 3.70 | 2.04 | 3.56 | 5.00 | 0.89 | 0.00 |
| 9 | VB | 6.05 | 0.74 | 0.50 | 1.36 | 0.16 | 0.26 | 3.64 | 1.65 | 3.21 | 1.95 | 0.87 | 0.00 |
| 17 | REL | 5.90 | 1.04 | 0.15 | 0.85 | 0.25 | 0.13 | 4.29 | 0.99 | 3.62 | 2.00 | 1.57 | 1.56 |
| 23 | REL | 5.82 | 0.93 | 0.80 | 2.81 | 0.66 | 0.42 | 3.92 | 1.44 | 3.27 | 1.40 | 0.92 | 0.00 |
| 1 | REL | 6.22 | 0.44 | 0.01 | 0.68 | 0.21 | 0.13 | 3.64 | 1.73 | 3.55 | 3.53 | 0.67 | 0.00 |
| 6 | REL | 6.23 | 0.39 | 0.01 | 0.44 | 0.09 | 0.07 | 3.77 | 2.55 | 3.73 | 3.80 | 0.62 | 0.00 |
| 13 | SVR | 6.10 | 1.11 | 0.26 | 1.16 | 0.27 | 0.11 | 4.19 | 2.33 | 3.68 | 3.00 | 1.54 | 2.22 |
|
Mean (± SD) |
SVR 8% |
6.23 (0.34) |
0.64 (0.33) |
0.21 (0.24) |
1.02 (0.9) |
0.24 (0.26) |
0.18 (0.18) |
3.90 (0.22) |
1.80 (0.49) |
3.63 (0.21) |
2.62 (1.17) |
0.81 (0.4) |
0.34 (0.72) |
| Caucasians | |||||||||||||
| 22 | VB | 6.29 | 0.85 | 0.64 | 1.60 | 0.24 | 0.22 | 4.10 | 1.28 | 3.14 | 0.96 | 0.93 | 0.00 |
| 16 | VB | 6.68 | 0.86 | 0.50 | 1.53 | 0.29 | 0.30 | 4.10 | 2.15 | 3.80 | 2.80 | 0.90 | 0.00 |
| 18 | REL | 6.25 | 0.65 | 0.59 | 1.75 | 0.54 | 0.16 | 3.81 | 2.31 | 3.54 | 2.36 | 0.74 | 0.00 |
| 12 | REL | 7.10 | 0.94 | 0.57 | 1.44 | 0.29 | 0.18 | 3.72 | 1.90 | 3.28 | 1.90 | 0.87 | 0.00 |
| 2 | REL | 6.90 | 0.71 | 0.39 | 1.91 | 0.70 | 0.05 | 3.87 | 2.56 | 3.42 | 1.35 | 0.54 | 0.00 |
| 10 | REL | 6.70 | 1.68 | 0.87 | 1.58 | 0.25 | 0.01 | 4.26 | 0.99 | 2.39 | 1.00 | 8.28 | 4.69 |
| 19 | SVR | 3.35 | 1.67 | 1.35 | 1.35 | 0.89 | ND c | 4.20 | 1.03 | 2.95 | ND c | 2.00 | 2.00 |
| 5 | SVR | 6.40 | 1.29 | 1.05 | 2.90 | 0.52 | 0.50 | 4.02 | 1.97 | 3.61 | 3.00 | 1.25 | 1.91 |
| 8 | SVR | 5.50 | 1.38 | 1.33 | 3.50 | 0.89 | 0.90 | 3.85 | 1.69 | 3.19 | 2.00 | 1.53 | 1.71 |
| 21 | SVR | 6.84 | 1.03 | 0.63 | 2.38 | 0.56 | 0.16 | 3.91 | 1.63 | 2.84 | 1.00 | 1.31 | 1.75 |
|
Mean (± SD) Difference |
SVR 40% N.S. |
6.20 (1.1) N.S. |
1.10 (0.38) P<0.02 |
0.79 (0.34) P<0.001 |
1.99 (0.71) P<0.01 |
0.52 (0.25) P<0.01 |
0.28 (0.27) N.S. |
3.98 (0.18) N.S. |
1.75 (0.53) N.S. |
3.21 (0.42) p<0.03 |
1.82 (0.79) N.S. |
1.84 (2.3) N.S. |
1.21 (1.53) N.S. |
a)
Minimal estimate due to negligible viral decline.
b)
Cannot be estimated due to negligible viral decline.
c)
Cannot be estimated due to rapid viral decline below detection level.